Search Results
Sep 29, 2025, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:51 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:39 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:35 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 17:28 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 29, 2025, 10:00 ET iQure Pharma Secures US Patent for iQ-007, a First-in-Class Small Molecule Restoring Glutamate Balance in CNS Disorders
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a US patent for iQure's clinical-stage asset iQ-007.
More news about: iQure Pharma Inc.
Sep 25, 2025, 07:37 ET Precision Medicine Protocol Shows Dual Benefits: Improved Cognition and Reduced Depression
have demonstrated that ReCODE can improve cognition in patients with early Alzheimer's and mild cognitive impairment. About CNS Vital Signs CNS Vital Signs is a leading provider of computerized neurocognitive assessments, offering clinicians efficient
More news about: Apollo Health
Sep 25, 2025, 07:00 ET Corero Network Security Enters Singapore Market Through Partnership with ONESECURE Asia
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced its strategic partnership
More news about: Corero Network Security
Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
NeurimmuneNeurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational
More news about: AL-S Pharma AG
Sep 25, 2025, 06:30 ET Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
central nervous system (CNS), including decreased number of pathogenic T helper cells producing interleukin-17A (IL-17A), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFNγ). Prophylactic dosing also increased expression of Nurr1 target genes in the CNS, elevated plasma brain-derived
More news about: Immunic, Inc.
Sep 24, 2025, 19:00 ET Corero Network Security Masuk Pasar Singapura Melalui Kemitraan Dengan ONESECURE Asia
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui di bidang perlindungan DDoS dan yang terbaik dalam hal ketersediaan layanan adaptif di waktu nyata.
More news about: Corero Network Security
Sep 24, 2025, 10:52 ET Cognision and SOMNOmedics Forge Strategic Partnership to Advance Sleep Biomarkers in Pharmaceutical Clinical Trials
gold-standard electroencephalography (EEG) and event-related potential (ERP) biomarkers. "Sleep endpoints are becoming increasingly important in CNS drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies," said Dr. Igor
More news about: Cognision
Sep 24, 2025, 10:00 ET FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience
Two Bear Capital. "Their platform is scaling across solid tumors and also unlocks CNS applications where clean, noninvasive signals are notoriously hard to capture. We're excited to support the natural expansion of their platform into
More news about: FYR Diagnostics
Sep 24, 2025, 07:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Beach, FL, US.Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting 2016; September
More news about: Novartis Pharmaceuticals Corporation
Sep 24, 2025, 02:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 23, 2025, 18:44 ET Cohen & Steers Closed-End Funds Declare Distributions for October, November and December 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 23, 2025, 11:30 ET Inna Topiler, Leading Hashimoto's & Thyroid Expert, Launches ThyroLove: A Revolutionary Thyroid Supplement
NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Inna Topiler, MS, CNS, founder of Complete Nutrition and Wellness and host of Thyroid Mystery Solved today announced the launch of ThyroLove, a breakthrough thyroid and immune
More news about: Complete Nutrition and Wellness
Sep 23, 2025, 07:00 ET Corero Network Security and Atlantic Data Security Form Strategic Business Resiliency Partnership
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced a new strategic partnership
More news about: Corero Network Security
Sep 22, 2025, 10:51 ET Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
innovative solutions in the CNS field, some of which are based on advanced technologies resulting from strategic alliances. Neuraxpharm remains focused on innovation and investment in new solutions with the goal of improving the quality of life for people with CNS disorders. The company is committed
More news about: Neuraxpharm
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) VORANIGO IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
More news about: Servier Pharmaceuticals
Sep 22, 2025, 07:45 ET Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
Sep 18, 2025, 18:37 ET Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Sep 18, 2025, 17:31 ET NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight
and neurological applications Because NF-κB signaling is implicated in Alzheimer's, Parkinson's, long-COVID neurological symptoms and other CNS disorders, pipeline activity aimed at neurodegeneration (and the need for blood-brain-barrier-permeable molecules) is expanding market opportunity. BioVie's
More news about: DelveInsight Business Research, LLP
Sep 18, 2025, 16:30 ET Cohen & Steers and Lincoln Property Company Form Joint Venture on Cityline at Tenley Retail Center in Washington, D.C.
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that funds managed by the Private Real Estate Group of Cohen & Steers and Lincoln Property Company have entered into a joint venture
More news about: Cohen & Steers, Inc.